Last reviewed · How we verify
ITI-333
At a glance
| Generic name | ITI-333 |
|---|---|
| Sponsor | Intra-Cellular Therapies, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers (PHASE1)
- A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects (PHASE1)
- Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ITI-333 CI brief — competitive landscape report
- ITI-333 updates RSS · CI watch RSS
- Intra-Cellular Therapies, Inc. portfolio CI